Clinical implications for substandard, nonproprietary medicines in multiple sclerosis: focus on fingolimod

Clinical implications for substandard, nonproprietary medicines in multiple sclerosis: focus on fingolimod

Jorge Correale,1 Erwin Chiquete,2 Alexey Boyko,3 Roy G Beran,4–6 Jorge Barahona Strauch,7,8 Snezana Milojevic,9 Nadina Frider101Department of Neurology, Raúl Carrea Institute for Neurological Research, Foundation for the Fight against Infant Neurological Illnesses (FLENI), Bueno...

Full description

Bibliographic Details
Main Authors: Correale J, Chiquete E, Boyko A, Beran RG, Strauch JB, Milojevic S, Frider N
Format: Article
Language:English
Published: Dove Medical Press 2016-06-01
Series:Drug Design, Development and Therapy
Subjects:
Bioequivalence
fingolimod
multiple sclerosis
proprietary
substandard copies
toxicity
Online Access:https://www.dovepress.com/clinical-implications-for-substandard-nonproprietary-medicines-in-mult-peer-reviewed-article-DDDT

Internet

https://www.dovepress.com/clinical-implications-for-substandard-nonproprietary-medicines-in-mult-peer-reviewed-article-DDDT

Similar Items